Mirion Technologies, Inc.

The stock remains in a deep corrective regime, trading well below its 200-day average after a long slide from the 52-week high of 30.277. It is still above the 52-week low of 15.58, so the setup is damaged but not broken.

Street sentiment stays constructive, with a Buy consensus and an average target of 26.75 versus a much lower share price. Recent calls have turned more cautious, with Morgan Stanley and Goldman Sachs trimming targets to 25 in July after earlier 2026 reductions.

The next print carries a mixed setup: Mirion has beaten in 5 of the last 7 quarters, but the most recent quarter missed and the upcoming period is still only estimated at 0.10 EPS. Full-year expectations still point higher, with 2026 EPS seen at 0.53732 versus 0.48715 for 2025.

Recent activity leans to net selling, but most of the table is award, vesting, or in-kind flow rather than discretionary trading. The only clear open-market signal is the 8,400-share sale by the Chief Accounting Officer, while the CEO’s large gift and multiple award grants are not bearish by themselves.

Profitability is modest but improving at the top line, with 27.5% revenue growth and a 47.1% gross margin. Net margin is only 2.56%, so earnings quality still depends on scaling operating leverage rather than strong current profitability.

Mirion’s niche in radiation detection and nuclear safety gives it exposure to regulated, high-spec industrial demand that many machinery peers do not have. The stock still trades at a premium-looking 34.02 P/E despite thin margins, so execution matters more than sector sympathy.